From: Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015
Male/Female
6/6
Age median (range)
78 (72–81)
<75/≥75
1/11
ECOG PS 0/1
Smoking (Current/former/never)
1/5/6
Stage IIIB/IV/Recurrent disease
2/8/2
Histology (adenocarcinoma/others)
12/0
Activating EGFR mutation (No/Yes/Unknown)
9/2/1